Jennifer Marie Reitman, NP

As part of MUSC Hollings Cancer Center, South Carolina's only NCI Designated Cancer Center, the MUSC Health Radiation Oncology team is committed to providing the best evidence-based care. Patients are often faced with a difficult decision regarding cancer treatment using surgery, chemotherapy or radiation therapy. Using our multidisciplinary approach to cancer care, we will work to determine the best treatment recommendations and deliver the highest quality care. Our staff of physicians, nurses, physicists, dosimetrists, therapists and clinical support staff are ready to answer any questions you have. Welcome and thank you for allowing us to participate in your care.

Patrick Flume is a Distinguished Professor of Medicine and Pediatrics at the Medical University of South Carolina. He serves as the Powers-Huggins Endowed Chair for Cystic Fibrosis and oversees a large Cystic Fibrosis (CF) Center, including the largest adult CF program in South Carolina. He also leads large clinical programs dedicated to patients with bronchiectasis and non-tuberculous mycobacterial (NTM) infections. He is recognized by the national and international CF community having served on the CF Foundation Center Committee, the Adult Care Consensus Committee, and the Advisory Task Force on Adult Issues, the Professional Education Committee, the European CF Society’s Best Practices committee, and as founding co-chair of the CF Foundation’s Pulmonary Practice Guidelines Committee. He co-led the International Working Group on Antimicrobial Resistance in Cystic Fibrosis. He is the Editor-in-Chief for the Journal of Cystic Fibrosis. He serves as Associate Vice President for Clinical Research at MUSC, leads a very busy clinical research program for CF, bronchiectasis, and NTM, and is co-principal investigator for the South Carolina Clinical & Translational Research Institute. Many of these studies are related to new drug and therapy development for patients, but he also has an interest in determining optimal management of CF pulmonary exacerbations and is the co-PI in the STOP trials, aimed at identifying optimal treatments for exacerbations.